Shelly Renee Cooper

Shelly Renee Cooper

Auto-generated profile, based on publicly available information

Shelly Renee Cooper

Brain and Spinal Injury Center, San Francisco General Hospital , San Francisco, California

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2013 in Journal of Neurotrauma
Verified
Journal Article
Closed access
John K YueJohn K Yue
John K Yue
MVMary J. Vassar
Mary J. Vassar
HLHester F. Lingsma
Hester F. Lingsma
SCShelly R. Cooper
Shelly R. Cooper
DODavid O. Okonkwo
David O. Okonkwo
TSTuhin K. Sinha
Tuhin K. Sinha
Traumatic brain injury (TBI) is among the leading causes of death and disability worldwide, with enormous negative social and economic impacts. The heterogeneity of TBI combined with the lack of precise outcome measures have been central to the discouraging results from clinical trials. Current approaches to the characterization of disease severity and outcome have not changed in more than three decades. This prospective multicenter observational pilot study aimed to validate the feasibility of implementing the TBI Common Data Elements (TBI-CDEs). A total of 650 subjects who underwent computed tomography (CT) scans in the emergency department within 24 h of injury were enrolled at three level I trauma centers and one rehabilitation center. The TBI-CDE components collected included: 1) demographic, social and clinical data; 2) biospecimens from blood drawn for genetic and proteomic biomarker analyses; 3) neuroimaging studies at 2 weeks using 3T magnetic resonance imaging (MRI); and 4) outcome assessments at 3 and 6 months. We describe how the infrastructure was established for building data repositories for clinical data, plasma biomarkers, genetics, neuroimaging, and multidimensional outcome measures to create a high quality and accessible information commons for TBI research. Risk factors for poor follow-up, TBI-CDE limitations, and implementation strategies are described. Having demonstrated the feasibility of implementing the TBI-CDEs through successful recruitment and multidimensional data collection, we aim to expand to additional study sites. Furthermore, interested researchers will be provided early access to the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) data set for collaborative opportunities to more precisely characterize TBI and improve the design of future clinical treatment trials. (ClinicalTrials.gov Identifier NCT01565551.)

1 September 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RRRichard Rubenstein
Richard Rubenstein
BCBinggong Chang
Binggong Chang
John K YueJohn K Yue
John K Yue
ACAllen Chiu
Allen Chiu
EWEthan A. Winkler
Ethan A. Winkler
MVMary J. Vassar
Mary J. Vassar
Traumatic brain injury (TBI), considered as an event and/or a disease, initiates a complex pathophysiologic central nervous system cascade with acute effects and secondary insults that may lead to chronic functional, neurocognitive, and neuropsychiatric deficits.1 Traumatic brain injury is classified according to its degree of severity (mild, moderate, and severe). In the United States, there are more than 3.5 million emergency department visits for TBI and more than 280 000 patients are hospitalized annually with TBI, with most of these classified as mild TBI (mTBI). There are also many more individuals with mTBI who never seek medical attention. More than 300 000 armed service members sustained TBI during combat and training from 2000 to 2014.2 Approximately half of patients with TBI in the United States incur at least some short-term disability.3 Traumatic brain injury is associated with an increased risk of neurodegenerative disorders, such as Alzheimer disease, years or decades after injury.4 In addition, repetitive mTBI is a risk factor for a neurodegenerative condition called chronic traumatic encephalopathy (CTE).5-7 Chronic traumatic encephalopathy, which can be confirmed only by postmortem neuropathologic examination, is defined by the abnormal accumulation of hyperphosphorylated tau protein (P-tau) in neurons, astroglia, and cell processes distributed around small blood vessels at the depth of cortical sulci in an irregular pattern.8

1 September 2014 in Journal of Neurotrauma
Verified
Journal Article
Closed access
EYEsther L. Yuh
Esther L. Yuh
SCShelly R. Cooper
Shelly R. Cooper
PMPratik Mukherjee
Pratik Mukherjee
John K YueJohn K Yue
John K Yue
HLHester F. Lingsma
Hester F. Lingsma
TSTuhin K. Sinha
Tuhin K. Sinha
We evaluated 3T diffusion tensor imaging (DTI) for white matter injury in 76 adult mild traumatic brain injury (mTBI) patients at the semiacute stage (11.2±3.3 days), employing both whole-brain voxel-wise and region-of-interest (ROI) approaches. The subgroup of 32 patients with any traumatic intracranial lesion on either day-of-injury computed tomography (CT) or semiacute magnetic resonance imaging (MRI) demonstrated reduced fractional anisotropy (FA) in numerous white matter tracts, compared to 50 control subjects. In contrast, 44 CT/MRI-negative mTBI patients demonstrated no significant difference in any DTI parameter, compared to controls. To determine the clinical relevance of DTI, we evaluated correlations between 3- and 6-month outcome and imaging, demographic/socioeconomic, and clinical predictors. Statistically significant univariable predictors of 3-month Glasgow Outcome Scale-Extended (GOS-E) included MRI evidence for contusion (odds ratio [OR] 4.9 per unit decrease in GOS-E; p=0.01), ≥1 ROI with severely reduced FA (OR, 3.9; p=0.005), neuropsychiatric history (OR, 3.3; p=0.02), age (OR, 1.07/year; p=0.002), and years of education (OR, 0.79/year; p=0.01). Significant predictors of 6-month GOS-E included ≥1 ROI with severely reduced FA (OR, 2.7; p=0.048), neuropsychiatric history (OR, 3.7; p=0.01), and years of education (OR, 0.82/year; p=0.03). For the subset of 37 patients lacking neuropsychiatric and substance abuse history, MRI surpassed all other predictors for both 3- and 6-month outcome prediction. This is the first study to compare DTI in individual mTBI patients to conventional imaging, clinical, and demographic/socioeconomic characteristics for outcome prediction. DTI demonstrated utility in an inclusive group of patients with heterogeneous backgrounds, as well as in a subset of patients without neuropsychiatric or substance abuse history.

1 September 2013 in Journal of Neurotrauma
Verified
Journal Article
Closed access
DODavid O. Okonkwo
David O. Okonkwo
John K YueJohn K Yue
John K Yue
APAva M. Puccio
Ava M. Puccio
DPDavid M. Panczykowski
David M. Panczykowski
TITomoo Inoue
Tomoo Inoue
GMGeoffrey T. Manley
Geoffrey T. Manley
Reliable diagnosis of traumatic brain injury (TBI) is a major public health need. Glial fibrillary acidic protein (GFAP) is expressed in the central nervous system, and breakdown products (GFAP-BDP) are released following parenchymal brain injury. Here, we evaluate the diagnostic accuracy of elevated levels of plasma GFAP-BDP in TBI. Participants were identified as part of the prospective Transforming Research And Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Study. Acute plasma samples (<24 h post-injury) were collected from patients presenting with brain injury who had CT imaging. The ability of GFAP-BDP level to discriminate patients with demonstrable traumatic lesions on CT, and with failure to return to pre-injury baseline at 6 months, was evaluated by the area under the receiver operating characteristic curve (AUC). Of the 215 patients included for analysis, 83% had mild, 4% had moderate, and 13% had severe TBI; 54% had acute traumatic lesions on CT. The ability of GFAP-BDP level to discriminate patients with traumatic lesions on CT as evaluated by AUC was 0.88 (95% confidence interval [CI], 0.84–0.93). The optimal cutoff of 0.68 ng/mL for plasma GFAP-BDP level was associated with a 21.61 odds ratio for traumatic findings on head CT. Discriminatory ability of unfavorable 6 month outcome was lower, AUC 0.65 (95% CI, 0.55–0.74), with a 2.07 odds ratio. GFAP-BDP levels reliably distinguish the presence and severity of CT scan findings in TBI patients. Although these findings confirm and extend prior studies, a larger prospective trial is still needed to validate the use of GFAP-BDP as a routine diagnostic biomarker for patient care and clinical research. The term “mild” continues to be a misnomer for this patient population, and underscores the need for evolving classification strategies for TBI targeted therapy. (ClinicalTrials.gov number NCT01565551; NIH Grant 1RC2 NS069409)

15 January 2015 in Journal of Neurotrauma
Verified
Journal Article
Closed access
HLHester F. Lingsma
Hester F. Lingsma
John K YueJohn K Yue
John K Yue
AMAndrew I.R. Maas
Andrew I.R. Maas
ESEwout W. Steyerberg
Ewout W. Steyerberg
GMGeoffrey T. Manley
Geoffrey T. Manley
EYEsther L. Yuh
Esther L. Yuh
Although the majority of patients with mild traumatic brain injury (mTBI) recover completely, some still suffer from disabling ailments at 3 or 6 months. We validated existing prognostic models for mTBI and explored predictors of poor outcome after mTBI. We selected patients with mTBI from TRACK-TBI Pilot, an unselected observational cohort of TBI patients from three centers in the United States. We validated two prognostic models for the Glasgow Outcome Scale Extended (GOS-E) at 6 months after injury. One model was based on the CRASH study data and another from Nijmegen, The Netherlands. Possible predictors of 3- and 6-month GOS-E were analyzed with univariate and multi-variable proportional odds regression models. Of the 386 of 485 patients included in the study (median age, 44 years; interquartile range, 27–58), 75% ( n =290) presented with a Glasgow Coma Score (GCS) of 15. In this mTBI population, both previously developed models had a poor performance (area under the receiver operating characteristic curve, 0.49–0.56). In multivariable analyses, the strongest predictors of lower 3- and 6-month GOS-E were older age, pre-existing psychiatric conditions, and lower education. Injury caused by assault, extracranial injuries, and lower GCS were also predictive of lower GOS-E. Existing models for mTBI performed unsatisfactorily. Our study shows that, for mTBI, different predictors are relevant as for moderate and severe TBI. These include age, pre-existing psychiatric conditions, and lower education. Development of a valid prediction model for mTBI patients requires further research efforts.

15 April 2015 in Journal of Neurotrauma
Verified
Journal Article
Closed access
PMPaul J. McMahon
Paul J. McMahon
DPDavid M. Panczykowski
David M. Panczykowski
John K YueJohn K Yue
John K Yue
APAva M. Puccio
Ava M. Puccio
TITomoo Inoue
Tomoo Inoue
MVMary J. Vassar
Mary J. Vassar
Glial fibrillary acidic protein and its breakdown products (GFAP-BDP) are brain-specific proteins released into serum as part of the pathophysiological response after traumatic brain injury (TBI). We performed a multi-center trial to validate and characterize the use of GFAP-BDP levels in the diagnosis of intracranial injury in a broad population of patients with a positive clinical screen for head injury. This multi-center, prospective, cohort study included patients 16–93 years of age presenting to three level 1 trauma centers with suspected TBI (loss of consciousness, post-trauma amnesia, and so on). Serum GFAP-BDP levels were drawn within 24 h and analyzed, in a blinded fashion, using sandwich enzyme-linked immunosorbent assay. The ability of GFAP-BDP to predict intracranial injury on admission computed tomography (CT) as well as delayed magnetic resonance imaging was analyzed by multiple regression and assessed by the area under the receiver operating characteristic curve (AUC). Utility of GFAP-BDP to predict injury and reduce unnecessary CT scans was assessed utilizing decision curve analysis. A total of 215 patients were included, of which 83% suffered mild TBI, 4% moderate, and 12% severe; mean age was 42.1±18 years. Evidence of intracranial injury was present in 51% of the sample (median Rotterdam Score, 2; interquartile range, 2). GFAP-BDP demonstrated very good predictive ability (AUC=0.87) and demonstrated significant discrimination of injury severity (odds ratio, 1.45; 95% confidence interval, 1.29–1.64). Use of GFAP-BDP yielded a net benefit above clinical screening alone and a net reduction in unnecessary scans by 12–30%. Used in conjunction with other clinical information, rapid measurement of GFAP-BDP is useful in establishing or excluding the diagnosis of radiographically apparent intracranial injury throughout the spectrum of TBI. As an adjunct to current screening practices, GFAP-BDP may help avoid unnecessary CT scans without sacrificing sensitivity (Registry: ClinicalTrials.gov Identifier: NCT01565551).